{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000083","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.259392+00:00","generated_at":"2026-06-08T12:30:23.565549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ligand Q3 adjusted EPS $1.02, revenue $32.9M; raises 2023 guidance; invests $75M+","bullets":["Q3 total revenue $32.9M; ex-COVID revenue $26.9M vs $26.9M prior year. Net loss $0.74 GAAP per share.","Adjusted net income $18.0M ($1.02 diluted EPS) vs $10.5M ($0.60) YoY; 2023 adjusted EPS guidance raised to $5.25-$5.40.","Royalties $23.9M (+24% YoY) led by Kyprolis, Rylaze, Vaxneuvance, Filspari. Core Captisol $8.6M vs $3.6M.","Invested over $75M in Q3/early Q4: $30M in Ovid soticlestat royalty, $20M for Tolerance/TZIELD royalty, $12.2M Novan purchase, $15M Primrose Bio.","New $75M revolving credit facility with Citibank; cash & investments $190.5M at Sept 30. Revenue guidance raised to $126-$129M."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000083","json":"https://secwatch.observer/filing/0000886163-23-000083.json","markdown":"https://secwatch.observer/filing/0000886163-23-000083.md","text":"https://secwatch.observer/filing/0000886163-23-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/0000886163-23-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/lgnd-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:30:23.565549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60ffe24ccfa6186b468b31d5cfed94f0f6bf90e5","claim":"LIGAND PHARMACEUTICALS INC updated its three and nine months ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 8, 2023, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000083/0000886163-23-000083-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}